{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:15:19Z","timestamp":1740136519473,"version":"3.37.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p\/><jats:sec><jats:title>OBJECTIVES<\/jats:title><jats:p>We investigated the influence of the preoperative haemoglobin A1c (HbA1c) value on the prognosis and pathology of patients with lung adenocarcinoma who underwent surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>We reviewed the medical records of 400 lung adenocarcinoma patients who underwent lobectomy with mediastinal lymph node dissection between 2009 and 2013 using a prospectively maintained database. We stratified 400 patients into 4 groups according to the preoperative HbA1c value as follows: HbA1c\u2009\u2264\u20095.9 (n\u2009=\u2009296), 6.0\u2009\u2264\u2009HbA1c\u2009\u2264\u20096.9 (n\u2009=\u200970), 7.0\u2009\u2264\u2009HbA1c\u2009\u2264\u20097.9 (n\u2009=\u200921) and HbA1c\u2009\u2265\u20098.0 (n\u2009=\u200912). We compared the recurrence-free survival and overall survival (OS) among these 4 groups. Univariate and multivariate analyses were performed to identify the risk factors for recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The median follow-up period was 61.2\u2009months. On comparing the recurrence-free survival and OS rates among these 4 groups, we found that these rates among patients in the HbA1c\u2009\u2265\u20098.0 group were significantly poorer compared with the other 3 groups (5-year recurrence-free survival: HbA1c\u2009\u2264\u20095.9, 70.4%; 6.0\u2009\u2264\u2009HbA1c\u2009\u2264\u20096.9, 69.7%; 7.0\u2009\u2264\u2009HbA1c\u2009\u2264\u20097.9, 70.7%; \u22658.0 HbA1c, 18.8%; P\u2009=\u20090.002; and 5-year OS: HbA1c\u2009\u2264\u20095.9, 88.7%; 6.0\u2009\u2264\u2009HbA1c\u2009\u2264\u20096.9, 80.6%; 7.0\u2009\u2264\u2009HbA1c\u2009\u2264\u20097.9, 90.2%; \u22658.0 HbA1c, 66.7%; P\u2009=\u20090.046). Patients in the HbA1c\u2009\u2265\u20098.0 group had significantly more tumours with vascular invasion (P\u2009=\u20090.041) and experienced distant metastasis significantly more often (P\u2009=\u20090.028) than those with other values. A multivariate analysis revealed that preoperative HbA1c\u2009\u2265\u20098.0 [hazard ratio (HR) 2.33; P\u2009=\u20090.026] and lymph node metastasis (HR 3.94; P\u2009&amp;lt;\u20090.001) were significant independent prognostic factors for recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Our results revealed that preoperative HbA1c\u2009\u2265\u20098.0 is associated to poor prognosis due to the occurrence of distant metastasis and we should carefully follow these patients after surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical registration number<\/jats:title><jats:p>Hyogo Cancer Center, G-57.<\/jats:p><\/jats:sec>","DOI":"10.1093\/icvts\/ivab140","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T11:10:46Z","timestamp":1619262646000},"page":"534-540","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic significance of preoperative haemoglobin A1c level in patients with lung adenocarcinoma"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-3997","authenticated-orcid":false,"given":"Hiroyuki","family":"Ogawa","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9240-6651","authenticated-orcid":false,"given":"Yusuke","family":"Fujibayashi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-1379","authenticated-orcid":false,"given":"Megumi","family":"Nishikubo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8324-4865","authenticated-orcid":false,"given":"Yuki","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3747-5088","authenticated-orcid":false,"given":"Shinya","family":"Tane","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-3940","authenticated-orcid":false,"given":"Yoshitaka","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1252-9935","authenticated-orcid":false,"given":"Wataru","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"2022030915262934500_ivab140-B1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends\u2014an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022030915262934500_ivab140-B2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"2022030915262934500_ivab140-B3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"2022030915262934500_ivab140-B4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"2022030915262934500_ivab140-B5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"2022030915262934500_ivab140-B6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"2022030915262934500_ivab140-B7","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/JTO.0b013e31822a75be","article-title":"Prolonged survival in patients with lung cancer with diabetes mellitus","volume":"6","author":"Hatlen","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2022030915262934500_ivab140-B8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3892\/mco.2017.1224","article-title":"Survival of patients with lung cancer and diabetes mellitus","volume":"6","author":"Kurishima","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"2022030915262934500_ivab140-B9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/CM9.0000000000000739","article-title":"Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer","volume":"133","author":"Wang","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"2022030915262934500_ivab140-B10","first-page":"513","article-title":"Protective effect of diabetes against metastasis in patients with non-small cell lung cancer","volume":"167","author":"Hanbali","year":"2007","journal-title":"Arch Intern Med"},{"key":"2022030915262934500_ivab140-B11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"2022030915262934500_ivab140-B12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1186\/s12885-015-2012-4","article-title":"Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer","volume":"15","author":"Imai","year":"2015","journal-title":"BMC Cancer"},{"key":"2022030915262934500_ivab140-B13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00595-017-1612-9","article-title":"The preoperative HbA1c level is an independent prognostic factor for the postoperative survival after resection of non-small cell lung cancer in elderly patients","volume":"48","author":"Motoishi","year":"2018","journal-title":"Surg Today"},{"key":"2022030915262934500_ivab140-B14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000323856","article-title":"Effect of diabetes mellitus on the outcome of patients with resected non-small cell lung carcinoma","volume":"57","author":"Bartling","year":"2011","journal-title":"Gerontology"},{"key":"2022030915262934500_ivab140-B15","doi-asserted-by":"crossref","first-page":"e3528","DOI":"10.1097\/MD.0000000000003528","article-title":"The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studies","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2022030915262934500_ivab140-B16","first-page":"217","article-title":"Metformin and not diabetes influences the survival of resected early stage NSCLC patients","volume":"6","author":"Dhillon","year":"2014","journal-title":"J Cancer Sci Ther"},{"key":"2022030915262934500_ivab140-B17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/JTO.0000000000000286","article-title":"Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18 FDG-PET for adenocarcinoma and squamous cell carcinoma","volume":"9","author":"Schuurbiers","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2022030915262934500_ivab140-B18","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1158\/0008-5472.CAN-17-2928","article-title":"GFPT2-expressing cancer-associated fibroblasts mediate metabolic reprogramming in human lung adenocarcinoma","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res"},{"key":"2022030915262934500_ivab140-B19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.08-0978","article-title":"The new lung cancer staging system","volume":"136","author":"Detterbeck","year":"2009","journal-title":"Chest"},{"key":"2022030915262934500_ivab140-B20","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/1097-0142(19900415)65:8<1864::AID-CNCR2820650832>3.0.CO;2-U","article-title":"Performance status assessment in cancer patients","volume":"65","author":"Conill","year":"1990","journal-title":"Cancer"},{"key":"2022030915262934500_ivab140-B21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.2040-1124.2012.00207.x","article-title":"International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values","volume":"3","author":"Kashiwagi","year":"2012","journal-title":"J Diabetes Investig"},{"key":"2022030915262934500_ivab140-B22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/jso.24989","article-title":"Prognostic factors for resected non-small cell lung cancer in patients with type 2 diabetes mellitus","volume":"117","author":"Yu","year":"2018","journal-title":"J Surg Oncol"},{"key":"2022030915262934500_ivab140-B23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc08-0545","article-title":"Translating the A1C assay into estimated average glucose values","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"key":"2022030915262934500_ivab140-B24","doi-asserted-by":"crossref","first-page":"e27074","DOI":"10.1371\/journal.pone.0027074","article-title":"High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR","volume":"6","author":"Han","year":"2011","journal-title":"PLoS One"},{"key":"2022030915262934500_ivab140-B25","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1158\/1078-0432.CCR-15-0375","article-title":"Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer","volume":"21","author":"De Rosa","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022030915262934500_ivab140-B26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12032-013-0805-3","article-title":"Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer","volume":"31","author":"Singh","year":"2014","journal-title":"Med Oncol"},{"key":"2022030915262934500_ivab140-B27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.devcel.2020.04.008","article-title":"Hyperinsulinemia drives epithelial tumorigenesis by abrogating cell competition","volume":"53","author":"Sanaki","year":"2020","journal-title":"Dev Cell"},{"key":"2022030915262934500_ivab140-B28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2407-13-170","article-title":"Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro","volume":"13","author":"Cardillo","year":"2013","journal-title":"BMC Cancer"},{"key":"2022030915262934500_ivab140-B29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0006-2952(00)00422-6","article-title":"Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy","volume":"60","author":"Brodt","year":"2000","journal-title":"Biochem Pharmacol"}],"container-title":["Interactive CardioVascular and Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/33\/4\/534\/42781540\/ivab140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/33\/4\/534\/42781540\/ivab140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T10:09:52Z","timestamp":1671962992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/icvts\/article\/33\/4\/534\/6296978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,11]]},"published-print":{"date-parts":[[2021,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/icvts\/ivab140","relation":{},"ISSN":["1569-9285"],"issn-type":[{"type":"electronic","value":"1569-9285"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,6,11]]}}}